绿康生化(002868) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥167,631,431.83, representing an increase of 86.67% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥39,414,819.22, a decrease of 26.15% year-on-year[5]. - Total operating revenue for Q3 2023 reached CNY 397.67 million, a significant increase from CNY 234.07 million in the same period last year, representing a growth of approximately 69.94%[27]. - The net profit for Q3 2023 was -86,624,964.66 CNY, compared to -68,093,068.62 CNY in Q3 2022, representing a decline of approximately 27.3% year-over-year[28]. - Total comprehensive income for the period was -86,624,964.66 CNY, compared to -68,093,068.62 CNY in Q3 2022, indicating a decline of approximately 27.3%[29]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,720,787,255.24, reflecting a growth of 38.79% from the end of the previous year[5]. - The total assets of the company as of September 30, 2023, were CNY 1.72 billion, an increase from CNY 1.24 billion at the start of the year, marking a growth of about 38.67%[25]. - The total liabilities increased to CNY 1.21 billion as of September 30, 2023, compared to CNY 640.56 million at the beginning of the year, representing an increase of approximately 88.59%[25]. - The company’s total equity attributable to shareholders decreased by 14.16% to ¥511,331,892.52 compared to the end of the previous year[5]. - The company's equity attributable to shareholders decreased to CNY 511.33 million from CNY 595.69 million, indicating a decline of about 14.12%[25]. Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of -¥122,560,703.12, a decrease of 806.79% year-to-date[5]. - The company reported a net cash outflow from operating activities of -122,560,703.12 CNY, worsening from -13,515,864.69 CNY in the previous year[31]. - Investment activities resulted in a net cash outflow of -123,889,163.94 CNY, compared to -122,104,829.11 CNY in the same period last year[31]. - Financing activities generated a net cash inflow of 440,797,609.14 CNY, significantly higher than 69,264,478.11 CNY in Q3 2022[31]. - The cash and cash equivalents at the end of the period stood at 220,317,856.07 CNY, up from 34,717,251.56 CNY at the end of Q3 2022[31]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,405[14]. - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.43% of shares, totaling 47,291,400 shares, with 2,090,000 shares pledged[14]. - The second largest shareholder, Shangrao Changxin No. 2 Enterprise Management Center, holds 10.00% of shares, totaling 15,541,584 shares[14]. - The company has a total of 2,011,507 shares in its repurchase account, accounting for 1.29% of the total share capital[15]. - The employee stock ownership plan involves a maximum of 2,011,507 shares, representing 1.29% of the current total share capital of 155,415,837 shares[19]. Employee Stock Ownership Plan - The employee stock ownership plan will unlock shares in three phases: 35% after 12 months, 35% after 24 months, and 30% after 36 months[19]. - The employee stock ownership plan accounted for 10.44% of the total shares, with a total investment of CNY 3.73 million from directors and senior management[21]. - The company has reserved a total of 95.06 million shares for future allocations, which represents 47.26% of the total employee stock ownership plan[21]. Operational Activities - The company is involved in a project for the production of 800 million square meters of photovoltaic film[18]. - The company has made several announcements regarding asset transfers and acquisitions, including the acquisition of 100% equity in Jiangxi Weike New Materials Technology Co., Ltd.[17]. - The company has established an employee stock ownership plan approved by the board of directors and the annual general meeting[18]. - The company has engaged in various financing and securities trading activities among its top shareholders[14]. Expenses - The company reported a significant increase in sales expenses, which rose by 51.36% to ¥10,859,795.61, reflecting higher costs associated with subsidiary operations[12]. - Total operating costs for Q3 2023 were CNY 471.64 million, up from CNY 289.94 million in the previous year, indicating an increase of about 62.67%[27]. - Research and development expenses increased to 19,620,456.15 CNY from 18,413,232.34 CNY, reflecting a rise of approximately 6.5% year-over-year[28]. Earnings Per Share - The basic earnings per share for the period was -¥0.26, down 30.00% compared to the same period last year[5]. - The basic and diluted earnings per share for Q3 2023 were both -0.56 CNY, compared to -0.44 CNY in the same quarter last year[29].